Compare Enveric Biosciences Inc (ENVB) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Open Text Corporation — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Open Text Corporation trades at $23.25 (market cap $5.62B). The key difference: Open Text Corporation is far larger — about 840.1× Enveric Biosciences Inc's market cap, and Open Text Corporation pays a 4.84% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Open Text Corporation for 23 Days on average.
| ENVB | OTEX | |
|---|---|---|
Market Cap | $6.69M | $5.62B |
Volume | 41,141 | 1,217,244 |
Sector | Health | Technology |
52-Week High | $10.80 | $39.69 |
52-Week Low | $1.27 | $20.01 |
Typical Hold Time | 14 Days | 23 Days |
Enterprise Value | -$1.60M | $10.64B |
Dividend Yield | — | 4.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
OpenText (OTEX) trades at $23.14, up 1.89% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with a P/E of 8.97 and consistent earnings beats, including Q2 2026 EPS of $1.23 beating expectations by 20.6%. Recent debt refinancing activities and a strategic AI partnership with Cohere highlight management's focus on growth and financial flexibility.
OTEX presents a compelling value opportunity with discounted valuation multiples and improving cloud momentum, though elevated debt levels and competitive pressures remain key risks. Analyst consensus targets $28.30 (22% upside) with 42% buy ratings, suggesting cautious optimism for the software company's transformation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
